Cost Management Insights: SG&A Expenses for Catalent, Inc. and TG Therapeutics, Inc.

SG&A Expenses: Catalent vs. TG Therapeutics Over a Decade

__timestampCatalent, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 201433480000024518692
Thursday, January 1, 201533730000019886580
Friday, January 1, 201635810000012631689
Sunday, January 1, 201740260000021977998
Monday, January 1, 201846260000020759000
Tuesday, January 1, 201951200000020838000
Wednesday, January 1, 2020577900000121812000
Friday, January 1, 2021687000000152137000
Saturday, January 1, 202284400000083231000
Sunday, January 1, 2023831000000122706000
Monday, January 1, 2024935000000
Loading chart...

Unleashing insights

Navigating SG&A Expenses: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, effective cost management is crucial. Catalent, Inc. and TG Therapeutics, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Catalent's SG&A expenses surged by approximately 179%, reflecting its aggressive growth strategy. In contrast, TG Therapeutics experienced a more volatile trajectory, with a notable spike in 2021, where expenses increased by over 600% compared to 2016. This dramatic rise underscores the company's strategic pivot towards expanding its market presence. However, the data for 2024 remains incomplete, leaving room for speculation on future trends. As these companies navigate the complexities of the pharmaceutical sector, their SG&A expenses provide a window into their strategic priorities and operational efficiencies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025